Jane Street
FBRX

Jane Street’s Forte Biosciences FBRX Stock Holding History

Jane Street’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-912
Closed -$67K – 10275
2021
Q3 		$67K Buy
+912
New +$505K ﹤0.01% 9448

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Jane Street's FBRX Position: Q2 2026 in Review

Jane Street reduced its Forte Biosciences (FBRX) stake by 64% in Q2 2026, selling an estimated $880K and leaving 20,805 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #8308.

Jane Street first reported a position in FBRX in Q2 2020 and has held it in 7 quarters since. The position peaked at $1.5M in Q1 2026. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Jane Street held 20,805 shares of Forte Biosciences worth $442K as of Q2 2026.
  • Jane Street sold 37,128 Forte Biosciences shares in Q2 2026, an estimated $880K.
  • Forte Biosciences made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #8308 holding.
  • Jane Street first reported a position in Forte Biosciences in Q2 2020 and has held it in 7 quarters since.
  • Jane Street's Forte Biosciences position peaked at $1.5M in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.